Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Plasma Mucin-1 (CA15-3) Levels in Autosomal Dominant Tubulointerstitial Kidney Disease due to MUC1 Mutations

P. Vylet'al, K. Kidd, HC. Ainsworth, D. Springer, A. Vrbacká, A. Přistoupilová, RP. Hughey, SL. Alper, N. Lennon, S. Harrison, M. Harden, V. Robins, A. Taylor, L. Martin, K. Howard, I. Bitar, CD. Langefeld, V. Barešová, H. Hartmannová, K....

. 2021 ; 52 (5) : 378-387. [pub] 20210607

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, pozorovací studie, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22012539

Grantová podpora
R21 DK106584 NIDDK NIH HHS - United States
U01 DK103225 NIDDK NIH HHS - United States

INTRODUCTION: Patients with ADTKD-MUC1 have one allele producing normal mucin-1 (MUC1) and one allele producing mutant MUC1, which remains intracellular. We hypothesized that ADTKD-MUC1 patients, who have only 1 secretory-competent wild-type MUC1 allele, should exhibit decreased plasma mucin-1 (MUC1) levels. To test this hypothesis, we repurposed the serum CA15-3 assay used to measure MUC1 in breast cancer to measure plasma MUC1 levels in ADTKD-MUC1. METHODS: This cross-sectional study analyzed CA15-3 levels in a reference population of 6,850 individuals, in 85 individuals with ADTKD-MUC1, and in a control population including 135 individuals with ADTKD-UMOD and 114 healthy individuals. RESULTS: Plasma CA15-3 levels (mean ± standard deviation) were 8.6 ± 4.3 U/mL in individuals with ADTKD-MUC1 and 14.6 ± 5.6 U/mL in controls (p < 0.001). While there was a significant difference in mean CA15-3 levels, there was substantial overlap between the 2 groups. Plasma CA15-3 levels were <5 U/mL in 22% of ADTKD-MUC1 patients, in 0/249 controls, and in 1% of the reference population. Plasma CA15-3 levels were >20 U/mL in 1/85 ADTKD-MUC1 patients, in 18% of control individuals, and in 25% of the reference population. Segregation of plasma CA15-3 levels by the rs4072037 genotype did not significantly improve differentiation between affected and unaffected individuals. CA15-3 levels were minimally affected by gender and estimated glomerular filtration rate. DISCUSSION/CONCLUSIONS: Plasma CA15-3 levels in ADTKD-MUC1 patients are approximately 40% lower than levels in healthy individuals, though there is significant overlap between groups. Further investigations need to be performed to see if plasma CA15-3 levels would be useful in diagnosis, prognosis, or assessing response to new therapies in this disorder.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012539
003      
CZ-PrNML
005      
20220506125757.0
007      
ta
008      
220425s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000515810 $2 doi
035    __
$a (PubMed)34098564
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Vylet'al, Petr $u Department of Paediatrics and Inherited Metabolic Disorders, Research Unit of Rare Diseases, First Faculty of Medicine, Charles University, Prague, Czechia
245    10
$a Plasma Mucin-1 (CA15-3) Levels in Autosomal Dominant Tubulointerstitial Kidney Disease due to MUC1 Mutations / $c P. Vylet'al, K. Kidd, HC. Ainsworth, D. Springer, A. Vrbacká, A. Přistoupilová, RP. Hughey, SL. Alper, N. Lennon, S. Harrison, M. Harden, V. Robins, A. Taylor, L. Martin, K. Howard, I. Bitar, CD. Langefeld, V. Barešová, H. Hartmannová, K. Hodaňová, T. Zima, M. Živná, S. Kmoch, AJ. Bleyer
520    9_
$a INTRODUCTION: Patients with ADTKD-MUC1 have one allele producing normal mucin-1 (MUC1) and one allele producing mutant MUC1, which remains intracellular. We hypothesized that ADTKD-MUC1 patients, who have only 1 secretory-competent wild-type MUC1 allele, should exhibit decreased plasma mucin-1 (MUC1) levels. To test this hypothesis, we repurposed the serum CA15-3 assay used to measure MUC1 in breast cancer to measure plasma MUC1 levels in ADTKD-MUC1. METHODS: This cross-sectional study analyzed CA15-3 levels in a reference population of 6,850 individuals, in 85 individuals with ADTKD-MUC1, and in a control population including 135 individuals with ADTKD-UMOD and 114 healthy individuals. RESULTS: Plasma CA15-3 levels (mean ± standard deviation) were 8.6 ± 4.3 U/mL in individuals with ADTKD-MUC1 and 14.6 ± 5.6 U/mL in controls (p < 0.001). While there was a significant difference in mean CA15-3 levels, there was substantial overlap between the 2 groups. Plasma CA15-3 levels were <5 U/mL in 22% of ADTKD-MUC1 patients, in 0/249 controls, and in 1% of the reference population. Plasma CA15-3 levels were >20 U/mL in 1/85 ADTKD-MUC1 patients, in 18% of control individuals, and in 25% of the reference population. Segregation of plasma CA15-3 levels by the rs4072037 genotype did not significantly improve differentiation between affected and unaffected individuals. CA15-3 levels were minimally affected by gender and estimated glomerular filtration rate. DISCUSSION/CONCLUSIONS: Plasma CA15-3 levels in ADTKD-MUC1 patients are approximately 40% lower than levels in healthy individuals, though there is significant overlap between groups. Further investigations need to be performed to see if plasma CA15-3 levels would be useful in diagnosis, prognosis, or assessing response to new therapies in this disorder.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a alely $7 D000483
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a průřezové studie $7 D003430
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a zdraví dobrovolníci pro lékařské studie $7 D064368
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mucin 1 $x krev $x genetika $7 D018396
650    _2
$a mutace $7 D009154
650    _2
$a intersticiální nefritida $x krev $x genetika $7 D009395
650    _2
$a prognóza $7 D011379
650    _2
$a uromodulin $x genetika $7 D058949
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kidd, Kendrah $u Department of Paediatrics and Inherited Metabolic Disorders, Research Unit of Rare Diseases, First Faculty of Medicine, Charles University, Prague, Czechia $u Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
700    1_
$a Ainsworth, Hannah C $u Division of Public Health Sciences, Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
700    1_
$a Springer, Drahomíra $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and the First Faculty of Medicine of Charles University, Prague, Czechia
700    1_
$a Vrbacká, Alena $u Department of Paediatrics and Inherited Metabolic Disorders, Research Unit of Rare Diseases, First Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Přistoupilová, Anna $u Department of Paediatrics and Inherited Metabolic Disorders, Research Unit of Rare Diseases, First Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Hughey, Rebecca P $u Renal-Electrolyte Division, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
700    1_
$a Alper, Seth L $u The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA $u Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
700    1_
$a Lennon, Niall $u The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
700    1_
$a Harrison, Steven $u The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
700    1_
$a Harden, Maegan $u The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
700    1_
$a Robins, Victoria $u Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
700    1_
$a Taylor, Abbigail $u Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
700    1_
$a Martin, Lauren $u Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
700    1_
$a Howard, Katrice $u Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
700    1_
$a Bitar, Ibrahim $u Biomedical Center and Institute of Microbiology, Faculty of Medicine in Pilsen of Charles University, Pilsen, Czechia
700    1_
$a Langefeld, Carl D $u Division of Public Health Sciences, Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
700    1_
$a Barešová, Veronika $u Department of Paediatrics and Inherited Metabolic Disorders, Research Unit of Rare Diseases, First Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Hartmannová, Hana $u Department of Paediatrics and Inherited Metabolic Disorders, Research Unit of Rare Diseases, First Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Hodaňová, Kateřina $u Department of Paediatrics and Inherited Metabolic Disorders, Research Unit of Rare Diseases, First Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Zima, Tomáš $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and the First Faculty of Medicine of Charles University, Prague, Czechia
700    1_
$a Živná, Martina $u Department of Paediatrics and Inherited Metabolic Disorders, Research Unit of Rare Diseases, First Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Kmoch, Stanislav $u Department of Paediatrics and Inherited Metabolic Disorders, Research Unit of Rare Diseases, First Faculty of Medicine, Charles University, Prague, Czechia $u Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
700    1_
$a Bleyer, Anthony J $u Department of Paediatrics and Inherited Metabolic Disorders, Research Unit of Rare Diseases, First Faculty of Medicine, Charles University, Prague, Czechia $u Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
773    0_
$w MED00000266 $t American journal of nephrology $x 1421-9670 $g Roč. 52, č. 5 (2021), s. 378-387
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34098564 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506125749 $b ABA008
999    __
$a ok $b bmc $g 1789938 $s 1163740
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 52 $c 5 $d 378-387 $e 20210607 $i 1421-9670 $m American journal of nephrology $n Am J Nephrol $x MED00000266
GRA    __
$a R21 DK106584 $p NIDDK NIH HHS $2 United States
GRA    __
$a U01 DK103225 $p NIDDK NIH HHS $2 United States
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace